Literature DB >> 28137493

Prehospital NSAIDs use prolong hospitalization in patients with pleuro-pulmonary infection.

Ourania S Kotsiou1, Sotirios G Zarogiannis2, Konstantinos I Gourgoulianis3.   

Abstract

OBJECTIVE: Nonsteroidal anti-inflammatory drug (NSAID) pre-hospitalization consumption might affect the course of pneumonia. We opted to assess the potential effects of pre-hospitalization use of NSAIDs in patients with pleuropulmonary infection in the context of the duration of hospitalization.
METHODS: A prospective observational study of 57 consecutive patients with a diagnosis of pneumonia and parapneumonic pleural effusion was conducted. The exact medication history the previous fifteen days was recorded.
RESULTS: Prehospital use of NSAIDs >6 days was positively associated with prolonged hospitalization extending out for approximately 10 days. Immunosuppression was an independent risk factor for prolonged hospitalization of more than 5 days. This group of patients also had more complicated pleural effusions and difficult to treat management. In the immunocompetent group of patients, there was a negative inverse correlation of duration of NSAIDs use with pleural fluid pH and glucose. The longer medication with NSAIDs correlated with lower values of C-reactive protein, and erythrocyte sedimentation rate. Importantly, the early prehospital antibiotic use significantly prevented the development of empyema.
CONCLUSION: Our findings highlight the potential complications involved with prehospital use of NSAIDs and especially that prolonged NSAID use which may lead to longer hospitalization duration and more complicated pleural effusions.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Community acquired pneumonia; Length of hospitalization; Nonsteroidal anti-inflammatory drugs; Pleural empyema; Pleural infection

Mesh:

Substances:

Year:  2016        PMID: 28137493     DOI: 10.1016/j.rmed.2016.12.005

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

Review 1.  Infectious pleural effusion status and treatment progress.

Authors:  Wei Yang; Bo Zhang; Ze-Ming Zhang
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

2.  Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.

Authors:  Thomas M Drake; Cameron J Fairfield; Riinu Pius; Stephen R Knight; Lisa Norman; Michelle Girvan; Hayley E Hardwick; Annemarie B Docherty; Ryan S Thwaites; Peter J M Openshaw; J Kenneth Baillie; Ewen M Harrison; Malcolm G Semple
Journal:  Lancet Rheumatol       Date:  2021-05-07

3.  Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?

Authors:  Mohit Sodhi; Mahyar Etminan
Journal:  Chest       Date:  2020-03-31       Impact factor: 9.410

4.  Polypharmacy at admission prolongs length of hospitalization in gastrointestinal surgery patients.

Authors:  Natsuki Abe; Takeyasu Kakamu; Tomohiro Kumagai; Tomoo Hidaka; Yusuke Masuishi; Shota Endo; Hideaki Kasuga; Tetsuhito Fukushima
Journal:  Geriatr Gerontol Int       Date:  2020-09-22       Impact factor: 2.730

5.  Pericardial Affections in Patients with COVID-19: A Possible Cause of Hemodynamic Deterioration.

Authors:  Fábio Fernandes; Felix José Alvarez Ramires; Fábio Danziato Fernandes; Marcus Vinicius Simões; Evandro Tinoco Mesquita; Charles Mady
Journal:  Arq Bras Cardiol       Date:  2020-09       Impact factor: 2.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.